Proton therapy for adult-type diffuse glioma: A systematic review

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2024-09-07 DOI:10.1016/j.critrevonc.2024.104501

Nicolas Goliot , Selim Mohssine , Dinu Stefan , Arthur Leclerc , Evelyne Emery , Jeanne Riverain , Fernand Missohou , Julien Geffrelot , William Kao , Samuel Valable , Jacques Balosso , Paul Lesueur

{"title":"Proton therapy for adult-type diffuse glioma: A systematic review","authors":"Nicolas Goliot , Selim Mohssine , Dinu Stefan , Arthur Leclerc , Evelyne Emery , Jeanne Riverain , Fernand Missohou , Julien Geffrelot , William Kao , Samuel Valable , Jacques Balosso , Paul Lesueur","doi":"10.1016/j.critrevonc.2024.104501","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>We conducted a systematic review to evaluate outcomes and toxicities associated with proton therapy in the treatment of adult-type diffuse glioma.</p></div><div><h3>Methods</h3><p>Following PRISMA guidelines, we searched PubMed for both prospective and retrospective studies on proton therapy for adult diffuse gliomas, including IDH-mutated gliomas WHO grade 2-3 and glioblastomas. Survival and toxicity outcomes were reported separately for these glioma types.</p></div><div><h3>Results</h3><p>Twelve studies from 2013 to 2023 were selected, comprising 3 prospective and 9 retrospective studies. The analysis covered 570 patients with WHO grade 2-3 gliomas and 240 patients with glioblastoma or WHO grade 4 gliomas. Proton therapy was found to be comparable to conventional radiotherapy in terms of survival outcomes. Its main advantage is the ability to minimize radiation exposure to healthy tissues.</p></div><div><h3>Discussion</h3><p>Proton therapy offers comparable survival outcomes to conventional radiotherapy for adult diffuse gliomas and may enhance treatment tolerance, especially regarding neurocognitive function. A major limitation of this review is the predominance of retrospective studies. Future research should ensure rigorous patient selection and adhere to the latest WHO 2021 classification</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104501"},"PeriodicalIF":5.5000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002440","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

We conducted a systematic review to evaluate outcomes and toxicities associated with proton therapy in the treatment of adult-type diffuse glioma.

Methods

Following PRISMA guidelines, we searched PubMed for both prospective and retrospective studies on proton therapy for adult diffuse gliomas, including IDH-mutated gliomas WHO grade 2-3 and glioblastomas. Survival and toxicity outcomes were reported separately for these glioma types.

Results

Twelve studies from 2013 to 2023 were selected, comprising 3 prospective and 9 retrospective studies. The analysis covered 570 patients with WHO grade 2-3 gliomas and 240 patients with glioblastoma or WHO grade 4 gliomas. Proton therapy was found to be comparable to conventional radiotherapy in terms of survival outcomes. Its main advantage is the ability to minimize radiation exposure to healthy tissues.

Discussion

Proton therapy offers comparable survival outcomes to conventional radiotherapy for adult diffuse gliomas and may enhance treatment tolerance, especially regarding neurocognitive function. A major limitation of this review is the predominance of retrospective studies. Future research should ensure rigorous patient selection and adhere to the latest WHO 2021 classification

查看原文本刊更多论文

质子治疗成人型弥漫性胶质瘤：系统综述。

背景我们进行了一项系统性综述，以评估质子疗法治疗成人型弥漫性胶质瘤的相关结果和毒性。方法根据PRISMA指南，我们在PubMed上检索了有关质子疗法治疗成人弥漫性胶质瘤（包括低级别胶质瘤和胶质母细胞瘤）的前瞻性和回顾性研究。结果选取了2013年至2023年的12项研究，包括3项前瞻性研究和9项回顾性研究。分析涵盖了570名低度胶质瘤患者和240名胶质母细胞瘤或WHO 4级胶质瘤患者。研究发现，质子疗法在生存率方面与传统放疗不相上下。讨论质子疗法为成人弥漫性胶质瘤提供了与传统放疗相当的生存率，并可提高治疗耐受性，尤其是在神经认知功能方面。本综述的一个主要局限是以回顾性研究为主。未来的研究应确保严格选择患者，并遵循最新的WHO 2021分类。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.